BEAM insider buying and SEC filings, explained
Beam Therapeutics Inc. · CIK 1745999
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Beam Therapeutics Inc.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$10.0M
Planned sales (10b5-1)
$9.7M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 15–16, 2026 | Planned (10b5-1) | John M. Evans (CEO and Director) sold 50,000 shares between Oct 15 and Oct 16 at about $23.77 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 5% to 1,047,205 shares. | SEC filing Filed Oct 16, 2026, 8:09 PM ET |
| Oct 1, 2026 | Planned (10b5-1) | Bethany J Cavanagh (SVP, Finance and Treasurer) sold 187 shares at $24.41 ($5K), marked as a 10b5-1 plan trade. Holdings down <1% to 50,984 shares. | SEC filing Filed Oct 2, 2026, 4:05 PM ET |
| Jul 27, 2026 | Planned (10b5-1) | Amy Simon (Chief Medical Officer) sold 16,667 shares at about $25.74 ($429K), marked as a 10b5-1 plan trade. Holdings down 16% to 85,696 shares. | SEC filing Filed Jul 29, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Amy Simon (Chief Medical Officer) sold 373 shares at $34.73 ($13K), marked as a 10b5-1 plan trade. Holdings down <1% to 102,363 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 29–30, 2026 | Planned (10b5-1) | John M. Evans (CEO and Director) sold 50,000 shares between Jun 29 and Jun 30 at about $34.90 ($1.7M), marked as a 10b5-1 plan trade. Holdings down 5% to 1,047,205 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 25–26, 2026 | Sale | FMR LLC (10% owner and See Remark 1) sold 284,860 shares indirectly (by entity) between Jun 25 and Jun 26 at about $35.24 ($10.0M). Holdings by entity down 25% to 854,583 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 29, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | John M. Evans (CEO and Director) sold 30,078 shares at $24.58 ($739K), marked as a 10b5-1 plan trade. Holdings down 3% to 1,047,205 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Amy Simon (Chief Medical Officer) sold 6,700 shares at $24.58 ($165K), marked as a 10b5-1 plan trade. Holdings down 6% to 102,735 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Bethany J Cavanagh (SVP, Finance and Treasurer) sold 3,242 shares at $24.58 ($80K), marked as a 10b5-1 plan trade. Holdings down 6% to 51,171 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Christine Bellon (Chief Legal Officer) sold 5,956 shares at $24.58 ($146K), marked as a 10b5-1 plan trade. Holdings down 5% to 109,711 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Giuseppe Ciaramella (President / COO) sold 11,810 shares at $24.58 ($290K), marked as a 10b5-1 plan trade. Holdings down 5% to 218,406 shares. | SEC filing Filed Apr 6, 2026 |
| Mar 30–31, 2026 | Planned (10b5-1) | John M. Evans (CEO and Director) sold 50,000 shares between Mar 30 and Mar 31 at about $22.57 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 5% to 986,667 shares. | SEC filing Filed Apr 1, 2026 |
| Feb 24, 2026 | Planned (10b5-1) | Giuseppe Ciaramella (President / COO) sold 35,000 shares at about $32.00 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 16% to 190,216 shares. | SEC filing Filed Feb 26, 2026 |
| Jan 29–30, 2026 | Planned (10b5-1) | John M. Evans (CEO and Director) sold 50,000 shares between Jan 29 and Jan 30 at about $28.87 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 5% to 986,667 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Bethany J Cavanagh (SVP, Finance and Treasurer) sold 6,198 shares at about $35.00 ($217K), marked as a 10b5-1 plan trade. Holdings down 15% to 34,813 shares. | SEC filing Filed Jan 26, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Christine Bellon (Chief Legal Officer) sold 1,371 shares at $34.00 ($47K), marked as a 10b5-1 plan trade. Holdings down 1% to 95,667 shares. | SEC filing Filed Jan 26, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Bethany J Cavanagh (SVP, Finance and Treasurer) sold 3,034 shares at $30.12 ($91K), marked as a 10b5-1 plan trade. Holdings down 7% to 41,011 shares. | SEC filing Filed Jan 21, 2026 |
| Jan 15, 2026 | Planned (10b5-1) | Christine Bellon (Chief Legal Officer) sold 18,629 shares at about $34.62 ($645K), marked as a 10b5-1 plan trade. Holdings down 16% to 97,038 shares. | SEC filing Filed Jan 20, 2026 |
| Dec 31, 2025 | Planned (10b5-1) | Sravan Kumar Emany (CFO) sold 6,294 shares at $27.10 ($171K), marked as a 10b5-1 plan trade. Holdings down 8% to 73,706 shares. | SEC filing Filed Jan 5, 2026 |
| Dec 31, 2025 | Planned (10b5-1) | Christine Bellon (Chief Legal Officer) sold 1,254 shares at $27.10 ($34K), marked as a 10b5-1 plan trade. Holdings down 1% to 115,667 shares. | SEC filing Filed Jan 5, 2026 |
24 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 8:34 AM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow BEAM in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.